Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Non-cash Items (2020 - 2022)

Ovid Therapeutics' Non-cash Items history spans 3 years, with the latest figure at $3.1 million for Q1 2022.

  • For Q1 2022, Non-cash Items fell 52.29% year-over-year to $3.1 million; the TTM value through Mar 2022 reached $3.1 million, down 52.29%, while the annual FY2021 figure was $2.4 million, 266.3% up from the prior year.
  • Non-cash Items reached $3.1 million in Q1 2022 per OVID's latest filing, up from $2.4 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $18.2 million in Q2 2020 to a low of $652438.0 in Q4 2020.
  • Average Non-cash Items over 3 years is $5.8 million, with a median of $3.1 million recorded in 2022.
  • The largest YoY upside for Non-cash Items was 266.3% in 2021 against a maximum downside of 71.26% in 2021.
  • A 3-year view of Non-cash Items shows it stood at $652438.0 in 2020, then soared by 266.3% to $2.4 million in 2021, then grew by 28.84% to $3.1 million in 2022.
  • Per Business Quant, the three most recent readings for OVID's Non-cash Items are $3.1 million (Q1 2022), $2.4 million (Q4 2021), and $3.0 million (Q3 2021).